Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pulse Biosciences, Inc.
< Previous
1
2
3
Next >
Pulse Biosciences Announces Plans to Initiate a Rights Offering
March 28, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
March 14, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
March 08, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
February 14, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
January 31, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
January 02, 2024
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
December 20, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
November 21, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
November 15, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
November 13, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call
November 10, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023
October 30, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery
October 24, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces Collaboration with CardioNXT for nsPFA First-in-Human Atrial Fibrillation Study
October 02, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
September 29, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences’ First Study in a Surgical Application of Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Two Poster Presentations at the American Thyroid Association Annual Meeting
September 27, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences to Present at Gilmartin Group Emerging Growth Showcase
September 07, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Clarifies Details of Recent S-3 Filing
August 24, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results
August 10, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Schedules Second Quarter 2023 Financial Results Conference Call for August 10, 2023
July 27, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting
May 18, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
May 11, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
May 10, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer
May 03, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Announces $65 Million Private Placement
May 01, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023
April 27, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results
March 30, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023
March 02, 2023
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Reports Third Quarter 2022 Financial Results
November 10, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022
October 27, 2022
From
Pulse Biosciences, Inc.
Via
Business Wire
Tickers
PLSE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.